Trial · NCT07561645
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
NCT07561645, Phase 2, Not yet recruiting, Technische Universität Dresden
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung. Trials, record NCT07561645. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07561645
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
- NCT number
- NCT07561645
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 75 participants, estimated
- Lead sponsor
- Technische Universität Dresden
- Conditions
- Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- Obrixtamig
- First posted
- 2026-05-01
- Last updated
- 2026-08-26
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | app. 69 months | To assess the efficacy of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC as measured by overall survival. |
| Secondary | Objective Response Rate (ORR) | app. 69 months | defined as PR or CR according to RECIST v1.1 as assessed by local investigator |
| Secondary | Progression-Free Survival (PFS) | app. 69 months | defined as time from first application of obrixtamig to progression according to RECIST v1.1, or to start of any other anticancer treatment, or death from any cause whichever occurs first |
| Secondary | Duration Of Response (DOR) | app. 69 months | defined as time from first documented PR or CR according to RECIST v1.1 to time of disease progression according to RECIST v1.1 or death from any cause, whichever occurs first |
| Secondary | Disease Control Rate (DCR) | app. 69 months | defined as combination of CR, PR and SD according to RECIST v1.1 |
| Secondary | immune Objective Response Rate (iORR) | app. 69 months | immune ORR (iORR) defined as iPR or iCR according to iRECIST |
| Secondary | immune Progression Free Survival (iPFS) | appr. 69 months | defined as time from first application of obrixtamig to progression according to iRECIST, clinical progression with change of treatment or death from any cause, whichever occurs first |
| Other | PFS, OS, DOR and ORR in central pathology confirmed cases of LCNEC | app. 69 months | |
| Other | PFS, OS, DOR and ORR in defined LCNEC molecular subtypes | appr. 69 months | (type I, type II - NSCLC and SCLC like) and depending on DLL3 expression to identify potential correlation between responses in molecular subtypes and DLL3 expression levels (high vs. low) |
| Other | Quality of Life assessment | appr. 69 months | Changes from baseline in EORTC-QLQ-C30 as well as QLQ-LC13 global and LC specific health/QoL score. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07561645
GET https://conductscience.org/api/trials/v1/NCT07561645/registered